Sakari H. Hietanen - Gynecology

Author Information

Sakari H. Hietanen is affiliated with the Department of Obstetrics and Gynecology at Turku University Hospital in Turku, Finland. His research primarily focuses on gynecological cancers, including ovarian and cervical cancers.

Research Contributions

Sakari H. Hietanen has made significant contributions to the field of gynecology, particularly in understanding and diagnosing various gynecological cancers. His work includes the development of new image analysis frameworks for RNA in situ hybridization and the study of molecular subtypes in endometrial carcinoma. He has also explored chemoresistance mechanisms in metastatic ovarian cancer and the role of tumor hypoxia in cervical cancer. Sakari's research has practical implications for improving diagnostic accuracy and treatment efficacy in gynecological oncology.

Aliases

S Hietanen, Sakari H. Hietanen, S. Hietanen, Sakari H Hietanen, Sakari Hietanen, S H Hietanen

Publication and Citation Metrics

Metric	Value
Citation Count	1524
H-index	18
Paper Count	117

Publications:

QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability

DOI: 10.1038/s41374-022-00743-5

Year: 2022

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer

DOI: 10.1126/sciadv.abm1831

Year: 2022

Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.

DOI: 10.1016/j.oraloncology.2022.105772

Year: 2022

DIMER, AND FIBRINOGEN FOR THE ASSESSMENT OF WOMEN PRESENTING WITH PELVIC MASSES

DOI:

Year: 2021

Molecular subtype diagnosis of endometrial carcinoma: comparison of NGS panel and ProMisE classifier.

DOI: 10.1016/j.humpath.2021.02.006

Year: 2021

Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer

DOI: 10.1097/RLU.0000000000003914

Year: 2021

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

DOI: 10.3390/cancers13081764

Year: 2021

FUNGI: FUsioN Gene Integration toolset

DOI: 10.1093/bioinformatics/btab206

Year: 2021

Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality

DOI: 10.1038/s41598-021-88382-6

Year: 2021

Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier

DOI: 10.1016/j.humpath.2021.02.006

Year: 2021

What role does socioeconomic status play in gynecological health disparities?

How Does High Resolution Ultrasonography Work?

Can Whole Grains Prevent Gynecological Conditions?

Why is BPD Important?

How to Apply for a Program?

How is Diabetes Related to Gynecological Cancers?

How is PIH Diagnosed?

How can gynecologists support emotional health?

What Are Allergy Tests?

Are there any ingredients to avoid in gynecological products?

Partnered Content Networks

Relevant Topics